Acumen Pharmaceuticals, Inc. (ABOS)

Market Cap	185.59M +189.0%
Revenue (ttm)	n/a
Net Income	-121.34M
EPS	-2.00
Shares Out	72.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	495,599
Open	2.660
Previous Close	2.670
Day's Range	2.535 - 2.670
52-Week Range	0.959 - 3.600
Beta	0.34
Analysts	Strong Buy
Price Target	8.00 (+211.28%)
Earnings Date	May 12, 2026

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 1, 2021
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: ABOS
• Website: https://acumenpharm.com

Analyst Summary

According to 2 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 211.28% from the latest price.

Price Target

$8.0

(211.28% upside)

Analyst Consensus: Strong Buy